"Global Pharmacogenomics Market Overview:
Global Pharmacogenomics Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global Pharmacogenomics Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Pharmacogenomics involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Pharmacogenomics Market:
The Pharmacogenomics Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Pharmacogenomics Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Pharmacogenomics Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Pharmacogenomics market has been segmented into:
DNA Sequencing
Microarray
Polymerase Chain Reaction
Electrophoresis
Mass Spectrometry
and Others
By Application, Pharmacogenomics market has been segmented into:
Cardiovascular Diseases
Infectious Diseases
Oncology
Neurological Diseases
Pain Management
and Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Pharmacogenomics market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Pharmacogenomics market.
Top Key Players Covered in Pharmacogenomics market are:
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd
Pharmigene
Abbott
Agilent Technologiesinc.
QIAGEN
GE HealthCare
Empire Genomicsinc.
Bio-Rad Laboratoriesinc.
Oxford Nanopore Technologies plc.
PerkinElmer Inc.
Myriad Geneticsinc.
Illuminainc.
Macrogeninc.
BGI Genomics
Eurofins Scientific
MapMyGenome
Invitae Corporation
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Pharmacogenomics Market by Type
4.1 Pharmacogenomics Market Snapshot and Growth Engine
4.2 Pharmacogenomics Market Overview
4.3 DNA Sequencing
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 DNA Sequencing: Geographic Segmentation Analysis
4.4 Microarray
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Microarray: Geographic Segmentation Analysis
4.5 Polymerase Chain Reaction
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Polymerase Chain Reaction: Geographic Segmentation Analysis
4.6 Electrophoresis
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Electrophoresis: Geographic Segmentation Analysis
4.7 Mass Spectrometry
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Mass Spectrometry: Geographic Segmentation Analysis
4.8 and Others
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 and Others: Geographic Segmentation Analysis
Chapter 5: Pharmacogenomics Market by Application
5.1 Pharmacogenomics Market Snapshot and Growth Engine
5.2 Pharmacogenomics Market Overview
5.3 Cardiovascular Diseases
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Cardiovascular Diseases: Geographic Segmentation Analysis
5.4 Infectious Diseases
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Infectious Diseases: Geographic Segmentation Analysis
5.5 Oncology
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Oncology: Geographic Segmentation Analysis
5.6 Neurological Diseases
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Neurological Diseases: Geographic Segmentation Analysis
5.7 Pain Management
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Pain Management: Geographic Segmentation Analysis
5.8 and Others
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 and Others: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Pharmacogenomics Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 THERMO FISHER SCIENTIFIC INC.
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 F. HOFFMANN-LA ROCHE LTD
6.4 PHARMIGENE
6.5 ABBOTT
6.6 AGILENT TECHNOLOGIESINC.
6.7 QIAGEN
6.8 GE HEALTHCARE
6.9 EMPIRE GENOMICSINC.
6.10 BIO-RAD LABORATORIESINC.
6.11 OXFORD NANOPORE TECHNOLOGIES PLC.
6.12 PERKINELMER INC.
6.13 MYRIAD GENETICSINC.
6.14 ILLUMINAINC.
6.15 MACROGENINC.
6.16 BGI GENOMICS
6.17 EUROFINS SCIENTIFIC
6.18 MAPMYGENOME
6.19 AND INVITAE CORPORATION
Chapter 7: Global Pharmacogenomics Market By Region
7.1 Overview
7.2. North America Pharmacogenomics Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 DNA Sequencing
7.2.4.2 Microarray
7.2.4.3 Polymerase Chain Reaction
7.2.4.4 Electrophoresis
7.2.4.5 Mass Spectrometry
7.2.4.6 and Others
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Cardiovascular Diseases
7.2.5.2 Infectious Diseases
7.2.5.3 Oncology
7.2.5.4 Neurological Diseases
7.2.5.5 Pain Management
7.2.5.6 and Others
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Pharmacogenomics Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 DNA Sequencing
7.3.4.2 Microarray
7.3.4.3 Polymerase Chain Reaction
7.3.4.4 Electrophoresis
7.3.4.5 Mass Spectrometry
7.3.4.6 and Others
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Cardiovascular Diseases
7.3.5.2 Infectious Diseases
7.3.5.3 Oncology
7.3.5.4 Neurological Diseases
7.3.5.5 Pain Management
7.3.5.6 and Others
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Pharmacogenomics Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 DNA Sequencing
7.4.4.2 Microarray
7.4.4.3 Polymerase Chain Reaction
7.4.4.4 Electrophoresis
7.4.4.5 Mass Spectrometry
7.4.4.6 and Others
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Cardiovascular Diseases
7.4.5.2 Infectious Diseases
7.4.5.3 Oncology
7.4.5.4 Neurological Diseases
7.4.5.5 Pain Management
7.4.5.6 and Others
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Pharmacogenomics Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 DNA Sequencing
7.5.4.2 Microarray
7.5.4.3 Polymerase Chain Reaction
7.5.4.4 Electrophoresis
7.5.4.5 Mass Spectrometry
7.5.4.6 and Others
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Cardiovascular Diseases
7.5.5.2 Infectious Diseases
7.5.5.3 Oncology
7.5.5.4 Neurological Diseases
7.5.5.5 Pain Management
7.5.5.6 and Others
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Pharmacogenomics Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 DNA Sequencing
7.6.4.2 Microarray
7.6.4.3 Polymerase Chain Reaction
7.6.4.4 Electrophoresis
7.6.4.5 Mass Spectrometry
7.6.4.6 and Others
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Cardiovascular Diseases
7.6.5.2 Infectious Diseases
7.6.5.3 Oncology
7.6.5.4 Neurological Diseases
7.6.5.5 Pain Management
7.6.5.6 and Others
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Pharmacogenomics Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 DNA Sequencing
7.7.4.2 Microarray
7.7.4.3 Polymerase Chain Reaction
7.7.4.4 Electrophoresis
7.7.4.5 Mass Spectrometry
7.7.4.6 and Others
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Cardiovascular Diseases
7.7.5.2 Infectious Diseases
7.7.5.3 Oncology
7.7.5.4 Neurological Diseases
7.7.5.5 Pain Management
7.7.5.6 and Others
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Pharmacogenomics Scope:
|
Report Data
|
Pharmacogenomics Market
|
|
Pharmacogenomics Market Size in 2025
|
USD XX million
|
|
Pharmacogenomics CAGR 2025 - 2032
|
XX%
|
|
Pharmacogenomics Base Year
|
2024
|
|
Pharmacogenomics Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Pharmigene, Abbott, Agilent Technologiesinc., QIAGEN, GE HealthCare, Empire Genomicsinc., Bio-Rad Laboratoriesinc., Oxford Nanopore Technologies plc., PerkinElmer Inc., Myriad Geneticsinc., Illuminainc., Macrogeninc., BGI Genomics, Eurofins Scientific, MapMyGenome, and Invitae Corporation.
|
|
Key Segments
|
By Type
DNA Sequencing
Microarray
Polymerase Chain Reaction
Electrophoresis
Mass Spectrometry
and Others
By Applications
Cardiovascular Diseases
Infectious Diseases
Oncology
Neurological Diseases
Pain Management
and Others
|
